good news research front mda quest magazine published update igf maria pennuto previous recipient kda research grant mda funding provided following update reporter amy madsen i written igf several previous posts potential hope hear promising news upcoming kda conference educational symposium second week october new orleans summary mice disease resembling spinal bulbar muscular atrophy sbma treated insulin like growth factor based compound better motor function slower weight loss improved muscle health increased survival time recent studies shown igf works sbma reducing toxicity caused mutation androgen receptor gene also helps promote muscle nerve growth new findings suggest igf potentially may effective ameliorating disease mice disease resembling spinal bulbar muscular atrophy sbma kennedy disease treated compound based insulin like growth factor igf better motor function slower weight loss healthier muscles longer survival time mice received inactive substance mda supported research team reported research team also found sbma mice overproduce muscle specific form igf milder disease course mice produce less protein new findings suggest igf potentially may effective ameliorating disease via least two mechanisms directly reducing toxicity caused mutation androgen receptor gene changing way androgen receptor protein behaves generally promoting regulating skeletal muscle growth improving survival muscle controlling nerve cells called motor neurons research team reported findings online aug molecular medicine read full report see igf administration ameliorates disease manifestations mouse model spinal bulbar muscular atrophy mda supported maria pennuto italian institute technology genoa italy findings show igf compounds hold therapeutic potential researchers treated sbma mice compound called mecasermin rinfabate brand name iplex combination igf igf binding protein binding protein helps igf last longer body male mice randomly assigned receive abdominal injections igf based compound daily dose milligrams per kilogram body weight inactive substance mimic typical clinical setting diagnosis sbma occurs symptoms appear researchers began injections mice weeks old disease onset continued weeks researchers evaluated body weight motor function survival mice found compared placebo treated mice treated igf less body weight loss significantly improved grip strength longer survival time average approximately three weeks addition researchers found igf treated mice markedly reduced muscle shrinkage atrophy degeneration study results provide basis study igf based compounds potential therapies people sbma